在一个患有卡布基综合征的儿童中,与氧化物相关的高糖血糖超状况
Harsh Kahlon1, Joshua R Stanley2,3, Cillian Lineen2,3
1Faculty of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
JCEM case reports
|July 1, 2024
概括
用于高胰岛素症的氧化物,很少会导致高血糖高位状态 (HHS). 早期识别和管理对于这种可能危及生命的疾病至关重要,如卡布基综合征的儿童所见.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 氧化是治疗超胰岛素症的主要治疗方法,这种疾病会导致胰岛素的过度产生.
- 虽然高血糖是众所周知的副作用,但严重的并发症,如高血糖超状况 (HHS) 是罕见的.
- 卡布基综合征是一种罕见的遗传疾病,可能与高胰岛素症有关.
研究的目的:
- 在患有卡布基综合征和高胰岛素症的儿童中报告第一个因二氧化物诱导的高糖血糖超状态 (HHS) 的病例.
- 强调识别和及时管理这种罕见的不良影响的重要性.
- 为了突出这一特定病例的临床表现和管理.
主要方法:
- 一个2岁女孩患有卡布基综合征和高胰岛素症的病例报告.
- 临床表现包括发烧,呼吸系统症状,疲和B型流感感染.
- 实验室发现显示HHS (高葡萄糖和度) 没有症或酸性.
主要成果:
- 患者在接受过氧化治疗时发展出高血糖高位状态 (HHS).
- 治疗方法包括停止服用氧化物和注射静脉液体.
- 超血糖症和超度症在不需要胰岛素治疗的情况下得到缓解,患者后来因低血糖症而重新开始服用二氧化.
结论:
- 氧化物诱导的HHS是一种罕见但严重的不良反应,需要迅速识别和管理.
- 这一案例凸显了接受氧化物治疗的超胰岛素症儿科患者需要保持警的必要性,特别是那些患有卡布基综合征等潜在遗传疾病的儿童.
- 早期干预可以预防与HHS相关的严重并发症.
相关概念视频
Hypoglycemia and Glucagon
254
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
254
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes: Symptoms, Diagnosis, and Complications
521
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
521
Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
Insulin: Dosing Regimen and Adverse Effects
165
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
165


